The Relationship Between Adropin Levels and the Slow Coronary Flow Phenomenon

Basit Öğe Kaydı
dc.authorid, Mustafa Cetin/0000-0001-7542-6602
dc.contributor.authorDemircelik, Bora
dc.contributor.authorKurtul, Alparslan
dc.contributor.authorOcek, Hakan
dc.contributor.authorCakmak, Muzaffer
dc.contributor.authorCetin, Mustafa
dc.contributor.authorUreyen, Cagin
dc.contributor.authorEryonucu, Beyhan
dc.date.accessioned2025-10-24T18:08:52Z
dc.date.available2025-10-24T18:08:52Z
dc.date.issued2015
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractThere is accumulating evidence that inflammation plays a major role in the development of the slow coronary flow (CSF) phenomenon. In this study, we aimed to study the new biomarker adroin levels as it relates to CSF. Patients who underwent coronary angiography before and had no significant epicardial coronary disease were included in the study. Patients who had thrombolysis in myocardial infarction frame counts (TFCs) above the normal cutoffs were considered to have CSF and those within normal limits were considered to have normal coronary flow (NCF). NCF group over the age of 30 were selected from patients with normal coronary arteries. The adropin levels and biochemical profiles of all patients were studied and analyzed with coronary flow parameters. There were 58 patients in the CSF group and 50 patients in the NCF group. The mean adropin level was significantly lower in CSF group than in NCF group (3.2 +/- 0.71 vs. 4.9 +/- 1.51 ng/mL, p < 0.001). There was a significant correlation between the adropin levels and TFC (r = -0.676, p < 0.001). Multivariable regression analysis showed that the adropin levels were an independent predictor of the CSF phenomenon (odds ratio = 1.041, 95 % confidence interval: 1.004-1.114, p = 0.014). In this study, we show that patients with CSF have decreased levels of adropin. We further show a strong correlation between the adropin levels and coronary blood flow. We conclude that decreased adropin levels might be a useful tool in predicting CSF in patients who undergo coronary angiography.
dc.identifier.doi10.1007/s12291-014-0470-0
dc.identifier.endpage417
dc.identifier.issn0970-1915
dc.identifier.issn0974-0422
dc.identifier.issue4
dc.identifier.scopus2-s2.0-84944317816
dc.identifier.scopusqualityQ3
dc.identifier.startpage412
dc.identifier.urihttps://doi.org/10.1007/s12291-014-0470-0
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3353
dc.identifier.volume30
dc.identifier.wosWOS:000217526200006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherSpringer India
dc.relation.ispartofIndian Journal Of Clinical Biochemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectAdropin; Inflamation; Coronary slow flow
dc.titleThe Relationship Between Adropin Levels and the Slow Coronary Flow Phenomenon
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu